Syndax Pharmaceuticals, Inc. (SNDX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SNDX Syndax Pharmaceuticals, Inc.

盘前交易 11-15 06:15:49 EST

16.79

+0.16

+0.96%

最高17.87	最低16.58	成交量218.65万
今开16.73	昨收16.63	日振幅7.76%
总市值14.33亿	流通市值14.27亿	总股本8,536万
成交额3,770万	换手率2.57%	流通股本8,502万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"SNDX","market":"US","secType":"STK","nameCN":"Syndax Pharmaceuticals, Inc. ","latestPrice":16.79,"timestamp":1731618000000,"preClose":16.63,"halted":0,"volume":2186450,"delay":0,"floatShares":85018096,"shares":85357675,"eps":-3.621743,"marketStatus":"盘前交易","marketStatusCode":1,"change":0.16,"latestTime":"11-15 06:15:49 EST","open":16.73,"high":17.87,"low":16.58,"amount":37697546.488,"amplitude":0.077571,"askPrice":19.53,"askSize":100,"bidPrice":15.09,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.621743,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1731681000000},"adr":0,"listingDate":1456981200000,"adjPreClose":16.79,"adrRate":0,"postHourTrading":{"tag":"盘后","latestPrice":16.6118,"preClose":16.79,"latestTime":"19:58 EST","volume":70457,"amount":1183013.9099,"timestamp":1731632283927},"volumeRatio":0.759633160860398,"optionData":{"bulkOrders":[{"symbol":"SNDX","call":true,"expireDate":1737090000000,"strike":"17.5","timestamp":1731609079508,"price":2.4000000953674316,"volume":4999,"amount":1199760,"type":"-"}]},"impliedVol":0.9342,"impliedVolPercentile":0.9124},"requestUrl":"/m/hq/s/SNDX","defaultTab":"news","newsList":[{"id":"2483666386","title":"Syndax Pharmaceuticals, Inc.盘中异动 早盘大幅上涨5.11%报17.48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483666386","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483666386?lang=zh_cn&edition=full","pubTime":"2024-11-15 00:20","pubTimestamp":1731601208,"startTime":"0","endTime":"0","summary":"北京时间2024年11月15日00时20分，Syndax Pharmaceuticals, Inc.股票出现波动，股价急速拉升5.11%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.52%。其相关个股中，Molecular Templates, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Pulmatrix, Inc.涨幅较大，Elevai Labs, Inc.、Molecular Templates, Inc.、Pulmatrix, Inc.较为活跃，换手率分别为2954.41%、1436.61%、327.72%，振幅较大的相关个股有Molecular Templates, Inc.、Pulmatrix, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为181.37%、112.92%、86.36%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115002008a23812c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115002008a23812c7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2483038330","title":"BUZZ-Syndax Pharma 因癌症治疗数据未达到 \"更高的预期标准 \"而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2483038330","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483038330?lang=zh_cn&edition=full","pubTime":"2024-11-13 00:15","pubTimestamp":1731428111,"startTime":"0","endTime":"0","summary":"BUZZ-Syndax Pharma 因癌症治疗数据未达到 \"更高的预期标准 \"而下跌11月12日 -  ** 药物开发商Syndax Pharmaceuticals SNDX.O股价下跌21.4%，至17.13美元，为近一年来最低点  ** 公司报告了癌症疗法的中期研究结果  ** Syndax称，该疗法的完全缓解率为23%，部分血液学恢复率为  ** 公司称，试验中11%的患者出现了严重的治疗相关不良事件，2%的患者出现了可能危及生命的事件  ** BTIG 分析师 Justin Zelin 说，今天股价疲软的原因是 \"从公司上次更新的情况来看，公司的形象受到了损害\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nL4T3MJ1WR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2482083627","title":"Syndax Pharmaceuticals, Inc.盘中异动 早盘股价大跌24.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482083627","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482083627?lang=zh_cn&edition=full","pubTime":"2024-11-12 22:30","pubTimestamp":1731421824,"startTime":"0","endTime":"0","summary":"北京时间2024年11月12日22时30分，Syndax Pharmaceuticals, Inc.股票出现异动，股价大幅跳水24.47%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Geovax Labs Inc C/Wts 29/09/2025、Cero Therapeutics Holdings, Inc.、Tc Biopharm  Plc C/Wts 10/02/2028 涨幅较大，Geovax Labs, Inc.、Cero Therapeutics Holdings, Inc.、Elevai Labs, Inc.较为活跃，换手率分别为103.77%、59.19%、43.20%，振幅较大的相关个股有Plus Therapeutics, Inc.、Enveric Biosciences, Inc.、Curevac N.V.，振幅分别为5.88%、5.45%、5.37%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111222302598e420ec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111222302598e420ec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2482267314","title":"Syndax Pharmaceuticals, Inc.2024财年第三财季实现净利润-84.13百万美元，同比减少64.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482267314","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482267314?lang=zh_cn&edition=full","pubTime":"2024-11-11 00:01","pubTimestamp":1731254493,"startTime":"0","endTime":"0","summary":"11月11日，Syndax Pharmaceuticals, Inc.公布财报，公告显示公司2024财年第三财季净利润为-84.13百万美元，同比减少64.48%；其中营业收入为12.50百万美元，每股基本收益为-0.98美元。机构评级：截至2024年11月11日，当前有14家机构对Syndax Pharmaceuticals, Inc.目标价做出预测，其中目标均价为35.86美元，其中最低目标价为23.00美元，最高目标价为47.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000212abb36320&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000212abb36320&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX"],"gpt_icon":0},{"id":"2480180918","title":"Syndax Pharmaceuticals Inc    预计每股亏损 1.11 美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2480180918","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480180918?lang=zh_cn&edition=full","pubTime":"2024-11-02 12:09","pubTimestamp":1730520570,"startTime":"0","endTime":"0","summary":"   * Syndax Pharmaceuticals Inc    将于11月5日公布截至2024年9月30日的财报，预计该公司的季度收入将有所增长。* 根据LSEG的数据，9位分析师的平均预期显示，这家总部位于马萨诸塞州沃尔瑟姆的公司预计将实现1119.9万美元的营收。* LSEG 分析师对 Syndax Pharmaceuticals Inc 的平均预期是每股亏损 1.11 美元。* 华尔街对 Syndax Pharmaceuticals Inc 的 12 个月目标价中位数为 35.00 美元，高于其最新收盘价 18.98 美元。11月2日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Syndax Pharmaceuticals Inc    预计每股亏损 1.11 美元 - 财报前瞻","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX"],"gpt_icon":0},{"id":"2474041283","title":"Syndax Pharmaceuticals, Inc.盘中异动 临近收盘股价大涨5.00%报19.11美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2474041283","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474041283?lang=zh_cn&edition=full","pubTime":"2024-10-12 03:33","pubTimestamp":1728675235,"startTime":"0","endTime":"0","summary":"北京时间2024年10月12日03时33分，Syndax Pharmaceuticals, Inc.股票出现波动，股价急速上涨5.00%。截至发稿，该股报19.11美元/股，成交量29.4292万股，换手率0.35%，振幅5.08%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.23%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410120333559719fbf6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410120333559719fbf6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2470031057","title":"Syndax Pharmaceuticals, Inc.盘中异动 股价大涨5.31%报19.13美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2470031057","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470031057?lang=zh_cn&edition=full","pubTime":"2024-09-28 00:59","pubTimestamp":1727456343,"startTime":"0","endTime":"0","summary":"北京时间2024年09月28日00时59分，Syndax Pharmaceuticals, Inc.股票出现异动，股价急速上涨5.31%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.80%。其相关个股中，Nls Pharmaceutics Ltd C/Wts 02/02/2026、Onconetix, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Onconetix, Inc.、Seelos Therapeutics, Inc.、Tonix Pharmaceuticals Holding Corp.较为活跃，换手率分别为4232.85%、260.28%、133.96%，振幅较大的相关个股有Pasithea Therapeutics Corp C/Wts 12/08/2026 、Estrella Immunopharma Inc C/Wts 29/09/2028、Estrella Immunopharma, Inc.，振幅分别为167.75%、69.81%、65.94%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240928005903a1dd1793&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240928005903a1dd1793&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2468398823","title":"Syndax Pharmaceuticals, Inc.盘中异动 快速下跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2468398823","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468398823?lang=zh_cn&edition=full","pubTime":"2024-09-17 01:06","pubTimestamp":1726506362,"startTime":"0","endTime":"0","summary":"北京时间2024年09月17日01时06分，Syndax Pharmaceuticals, Inc.股票出现异动，股价大幅下跌5.02%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.04%。其相关个股中，Nucana Plc、Surrozen Inc C/Wts 01/08/2031 、Tc Biopharm  Plc C/Wts 10/02/2028 涨幅较大，Nucana Plc、Dermata Therapeutics, Inc.、Exicure, Inc.较为活跃，换手率分别为2154.82%、1633.80%、1009.26%，振幅较大的相关个股有Psyence Biomedical Ltd C/Wts 25/01/2029、Nucana Plc、Tevogen Bio Holdings Inc C/Wts 14/02/2029 ，振幅分别为117.33%、69.69%、66.08%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240917010603a1da94bd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240917010603a1da94bd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2459403760","title":"BUZZ-美国食品和药物管理局批准 Syndax 治疗慢性移植物抗宿主病，该公司业绩上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2459403760","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459403760?lang=zh_cn&edition=full","pubTime":"2024-08-16 01:37","pubTimestamp":1723743463,"startTime":"0","endTime":"0","summary":"    8月15日 - ** Syndax制药公司  的股票在下午的交易中上涨了4%，达到20.37美元。** 美国食品和药物管理局周三晚些时候批准了  Syndax和合作伙伴Incyte公司  的药物Niktimvo，用于治疗慢性移植物抗宿主疾病患者(GvHD。** Niktimvo获准用于先前至少两种疗法失败的成人和儿童患者。** 该批准为Niktimvo在三线治疗市场与赛诺菲  的Rezurock竞争提供了 \"差异化机制\"--BTIG分析师。** Syndax和Incyte计划在2024年第四季度推出Niktimvo，并在上市时公布定价 ** 包括盘中涨幅在内，该股今年累计下跌约 4","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BUZZ","SNDX","BK4550","INCY","BK4588","BK4139","BK4532","BK4585"],"gpt_icon":0},{"id":"2459425477","title":"Syndax Pharmaceuticals, Inc.盘中异动 大幅拉升5.06%报20.57美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2459425477","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459425477?lang=zh_cn&edition=full","pubTime":"2024-08-16 00:14","pubTimestamp":1723738489,"startTime":"0","endTime":"0","summary":"北京时间2024年08月16日00时14分，Syndax Pharmaceuticals, Inc.股票出现异动，股价快速拉升5.06%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.36%。其相关个股中，Cingulate Inc.、Nls Pharmaceutics Ltd C/Wts 02/02/2026、Nutriband Inc C/Wts 涨幅较大，Cingulate Inc.、Scisparc Ltd.、Altamira Therapeutics Ltd.较为活跃，换手率分别为7178.21%、2216.80%、602.35%，振幅较大的相关个股有Nutriband Inc C/Wts 、Seastar Medical Holding Corp C/Wts 28/10/2027 、Nls Pharmaceutics Ltd C/Wts 02/02/2026，振幅分别为115.79%、103.98%、103.00%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240816001449a1d47575&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240816001449a1d47575&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2458515730","title":"Syndax Pharmaceuticals, Inc.2024财年第二财季实现净利润-68.06百万美元，同比减少52.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2458515730","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458515730?lang=zh_cn&edition=full","pubTime":"2024-08-10 00:22","pubTimestamp":1723220520,"startTime":"0","endTime":"0","summary":"8月10日，Syndax Pharmaceuticals, Inc.公布财报，公告显示公司2024财年第二财季净利润为-68.06百万美元，同比减少52.53%；其中营业收入为3.50百万美元，每股基本收益为-0.80美元。机构评级：截至2024年8月10日，当前有13家机构对Syndax Pharmaceuticals, Inc.目标价做出预测，其中目标均价为34.31美元，其中最低目标价为23.00美元，最高目标价为45.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240810002204958c4db8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240810002204958c4db8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX"],"gpt_icon":0},{"id":"2457775267","title":"Syndax Pharmaceuticals, Inc.盘中异动 急速下挫5.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2457775267","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457775267?lang=zh_cn&edition=full","pubTime":"2024-08-05 21:32","pubTimestamp":1722864769,"startTime":"0","endTime":"0","summary":"北京时间2024年08月05日21时32分，Syndax Pharmaceuticals, Inc.股票出现波动，股价快速下跌5.63%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为1.36%。其相关个股中，Zevra Therapeutics, Inc.、Alzamend Neuro, Inc.、Cns Pharmaceuticals, Inc.涨幅较大，Cns Pharmaceuticals, Inc.、Dermata Therapeutics, Inc.、Senti Biosciences, Inc.较为活跃，换手率分别为981.75%、35.48%、13.54%，振幅较大的相关个股有Vor Biopharma Inc.、Cue Biopharma, Inc.、Compass Therapeutics, Inc.，振幅分别为13.04%、12.33%、12.19%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240805213249957f2e71&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240805213249957f2e71&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2455915663","title":"Syndax Pharmaceuticals Inc    预计每股亏损 91 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2455915663","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455915663?lang=zh_cn&edition=full","pubTime":"2024-07-31 07:22","pubTimestamp":1722381741,"startTime":"0","endTime":"0","summary":"   * Syndax Pharmaceuticals Inc    将于8月1日公布截至2024年6月30日的财报，预计季度营收将保持不变。*    * LSEG分析师对Syndax Pharmaceuticals Inc的平均预期是每股亏损91美分。* 华尔街对 Syndax Pharmaceuticals Inc 的 12 个月目标价中位数为 35.00 美元，高于其上次收盘价 22.41 美元。7月30日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX"],"gpt_icon":0},{"id":"2455866513","title":"Syndax Pharmaceuticals, Inc.盘中异动 早盘大幅下跌14.25%报21.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2455866513","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455866513?lang=zh_cn&edition=full","pubTime":"2024-07-29 21:31","pubTimestamp":1722259914,"startTime":"0","endTime":"0","summary":"北京时间2024年07月29日21时31分，Syndax Pharmaceuticals, Inc.股票出现波动，股价快速跳水14.25%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.02%。其相关个股中，Lipella Pharmaceuticals Inc.、Nls Pharmaceutics Ltd.、Anew Medical Inc C/Wts 21/06/2029 涨幅较大，Lipella Pharmaceuticals Inc.、Palisade Bio, Inc.、Nls Pharmaceutics Ltd.较为活跃，换手率分别为1257.40%、135.75%、115.12%，振幅较大的相关个股有Lipella Pharmaceuticals Inc.、Nls Pharmaceutics Ltd.、Jasper Therapeutics Inc C/Wts 24/09/2026 ，振幅分别为56.92%、28.26%、25.18%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407292131549566fce4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407292131549566fce4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2454872307","title":"Syndax Pharmaceuticals, Inc.盘中异动 急速拉升5.00%报24.67美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2454872307","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454872307?lang=zh_cn&edition=full","pubTime":"2024-07-25 22:19","pubTimestamp":1721917174,"startTime":"0","endTime":"0","summary":"北京时间2024年07月25日22时19分，Syndax Pharmaceuticals, Inc.股票出现波动，股价急速拉升5.00%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.89%。其相关个股中，Psyence Biomedical Ltd.、Salarius Pharmaceuticals, Inc.、Ocean Biomedical Inc C/Wts 14/02/2028 涨幅较大，Salarius Pharmaceuticals, Inc.、Psyence Biomedical Ltd.、Azitra Inc较为活跃，换手率分别为2088.64%、415.87%、164.74%，振幅较大的相关个股有Psyence Biomedical Ltd.、Salarius Pharmaceuticals, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为114.90%、98.60%、82.05%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240725221935af941fe2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240725221935af941fe2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2452216202","title":"Syndax Pharmaceuticals, Inc.盘中异动 股价大跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452216202","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452216202?lang=zh_cn&edition=full","pubTime":"2024-07-18 00:48","pubTimestamp":1721234905,"startTime":"0","endTime":"0","summary":"北京时间2024年07月18日00时48分，Syndax Pharmaceuticals, Inc.股票出现波动，股价大幅跳水5.00%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为2.21%。其相关个股中，Aptevo Therapeutics Inc.、Geovax Labs Inc C/Wts 29/09/2025、Conduit Pharmaceuticals Inc C/Wts 22/09/2028涨幅较大，Aptevo Therapeutics Inc.、Aditxt, Inc.、Longeveron Inc.较为活跃，换手率分别为3323.58%、1382.05%、294.53%，振幅较大的相关个股有Aptevo Therapeutics Inc.、Aditxt, Inc.、4D Molecular Therapeutics, Inc.，振幅分别为76.39%、46.25%、45.71%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407180048259681db94&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407180048259681db94&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2450074235","title":"Syndax Pharmaceuticals, Inc.盘中异动 股价大涨5.02%报22.19美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450074235","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2450074235?lang=zh_cn&edition=full","pubTime":"2024-07-10 03:22","pubTimestamp":1720552938,"startTime":"0","endTime":"0","summary":"北京时间2024年07月10日03时22分，Syndax Pharmaceuticals, Inc.股票出现波动，股价大幅上涨5.02%。截至发稿，该股报22.19美元/股，成交量49.6093万股，换手率0.58%，振幅6.34%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.83%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240710032218941f57e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240710032218941f57e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2448949937","title":"Syndax Pharmaceuticals, Inc.盘中异动 下午盘大幅拉升5.11%报21.58美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448949937","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448949937?lang=zh_cn&edition=full","pubTime":"2024-07-02 02:38","pubTimestamp":1719859139,"startTime":"0","endTime":"0","summary":"北京时间2024年07月02日02时38分，Syndax Pharmaceuticals, Inc.股票出现波动，股价急速上涨5.11%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.84%。其相关个股中，Senti Biosciences, Inc.、Tevogen Bio Holdings Inc C/Wts 14/02/2029 、Seastar Medical Holding Corporation涨幅较大，Senti Biosciences, Inc.、Geovax Labs, Inc.、Tonix Pharmaceuticals Holding Corp.较为活跃，换手率分别为765.20%、202.08%、122.99%，振幅较大的相关个股有Senti Biosciences, Inc.、Cingulate Inc.、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 ，振幅分别为101.49%、82.81%、56.57%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240702023859af900bc7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240702023859af900bc7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2446025355","title":"Syndax Pharmaceuticals(SNDX.US)获杰富瑞投资银行首次覆盖，给予买入评级, 目标价37.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2446025355","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446025355?lang=zh_cn&edition=full","pubTime":"2024-06-28 20:48","pubTimestamp":1719578929,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2445798214","title":"Syndax Pharmaceuticals, Inc.盘中异动 下午盘快速拉升5.03%报20.24美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2445798214","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2445798214?lang=zh_cn&edition=full","pubTime":"2024-06-22 01:36","pubTimestamp":1718991366,"startTime":"0","endTime":"0","summary":"北京时间2024年06月22日01时36分，Syndax Pharmaceuticals, Inc.股票出现异动，股价急速拉升5.03%。截至发稿，该股报20.24美元/股，成交量35.8686万股，换手率0.42%，振幅4.31%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.18%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240622013607941f02b1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240622013607941f02b1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.syndax.com","stockEarnings":[{"period":"1week","weight":-0.2198},{"period":"1month","weight":-0.1499},{"period":"3month","weight":-0.1576},{"period":"6month","weight":-0.1725},{"period":"1year","weight":0.1149},{"period":"ytd","weight":-0.223}],"compareEarnings":[{"period":"1week","weight":-0.0038},{"period":"1month","weight":0.0234},{"period":"3month","weight":0.0704},{"period":"6month","weight":0.1207},{"period":"1year","weight":0.3195},{"period":"ytd","weight":0.2483}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Syndax Pharmaceuticals, Inc.于2005年10月11日根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司，正在开发癌症疗法的创新管道。该公司正在开发revumenib，这是一种有效的、选择性的、menin-MLL结合相互作用的小分子抑制剂，用于治疗KMT2A重排或KMT2AR，也称为混合谱系白血病重排或MLLR，包括急性淋巴细胞白血病或ALL在内的急性白血病，以及急性髓细胞白血病或AML，以及necleophosmin 1，也称为NPM1，突变AML。","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.044305},{"month":2,"riseRate":0.625,"avgChangeRate":0.07889},{"month":3,"riseRate":0.625,"avgChangeRate":0.084467},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.000613},{"month":5,"riseRate":0.444444,"avgChangeRate":0.006686},{"month":6,"riseRate":0.555556,"avgChangeRate":0.008456},{"month":7,"riseRate":0.555556,"avgChangeRate":0.011483},{"month":8,"riseRate":0.555556,"avgChangeRate":0.046113},{"month":9,"riseRate":0.555556,"avgChangeRate":-0.028471},{"month":10,"riseRate":0.222222,"avgChangeRate":-0.074254},{"month":11,"riseRate":0.555556,"avgChangeRate":0.001799},{"month":12,"riseRate":0.5,"avgChangeRate":0.063584}],"exchange":"NASDAQ","name":"Syndax Pharmaceuticals, Inc. ","nameEN":"Syndax Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Syndax Pharmaceuticals, Inc. (SNDX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Syndax Pharmaceuticals, Inc. (SNDX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Syndax Pharmaceuticals, Inc. ,SNDX,Syndax Pharmaceuticals, Inc. 股票,Syndax Pharmaceuticals, Inc. 股票老虎,Syndax Pharmaceuticals, Inc. 股票老虎国际,Syndax Pharmaceuticals, Inc. 行情,Syndax Pharmaceuticals, Inc. 股票行情,Syndax Pharmaceuticals, Inc. 股价,Syndax Pharmaceuticals, Inc. 股市,Syndax Pharmaceuticals, Inc. 股票价格,Syndax Pharmaceuticals, Inc. 股票交易,Syndax Pharmaceuticals, Inc. 股票购买,Syndax Pharmaceuticals, Inc. 股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Syndax Pharmaceuticals, Inc. (SNDX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Syndax Pharmaceuticals, Inc. (SNDX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}